prostate cancer

Pfizer shares rise on Phase 3 prostate cancer trial win and Phase 2 breast cancer success, validating its oncology pipeline and signaling near-term regulatory catalysts.

MDxHealth's genomic prostate cancer test demonstrates strong predictive performance across treatment settings, supporting path toward randomized clinical trial validation.

Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.

Kyntra Bio will report fourth quarter and full year 2025 financial results on March 16, 2026, as the biopharmaceutical company advances its oncology and rare disease pipeline.

Telix Pharmaceuticals announces March 2026 webinar on PSMA-PET/CT imaging innovations, featuring leading oncology experts discussing prostate cancer detection advances.

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.

Candel Therapeutics raises $100M via public share offering to fund commercialization of its prostate cancer gene therapy and ongoing lung cancer clinical trials.

Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.